---
marp: true
theme: uncover
paginate: true
backgroundColor: #ffffff
style: |
  section {
    font-family: 'Helvetica', sans-serif;
    text-align: left;
    font-size: 22px;
    padding: 40px;
  }
  h1 { font-size: 40px; }
  h2 { font-size: 32px; }
  h3 { font-size: 26px; }
  footer { font-size: 14px; color: #7f8c8d; }
  .columns {
    display: grid;
    grid-template-columns: repeat(2, minmax(0, 1fr));
    gap: 1rem;
  }

title: Medicinal Chemistry of Nonbenzodiazepine Sedative-Hypnotics
footer: "PHA 548 | Hampton University | PY1 PharmD"
---

# üåô Nonbenzodiazepine Sedative-Hypnotics (‚ÄúZ-Drugs‚Äù & Friends)

**Course:** PHA 548 Pharmacology & Medicinal Chemistry  
**Instructor:** Sidney Bolden, Jr., Ph.D.

---

## üéØ Learning Objectives (PY1 ‚Äì MedChem Focus)

By the end of this 75‚Äì90 min session, you should be able to:

1. **Compare** the nonbenzodiazepine BZD-site agonist pharmacophore (‚ÄúZ-drugs‚Äù) with classical benzodiazepines.  
   - *Bloom:* Understand / Apply  

2. **Relate** structural features of zolpidem, zaleplon, and eszopiclone to their **GABA\_A BZD-site selectivity**, onset, and duration.  
   - *Bloom:* Analyze  

3. **Predict** the impact of specific functional group changes (e.g., heteroatoms, lipophilic tails, amide/urea motifs) on PK and receptor subtype preference.  
   - *Bloom:* Analyze / Evaluate  

4. **Evaluate** how these ‚Äúdesigned‚Äù hypnotics attempt to minimize adverse effects (respiratory depression, tolerance, next-day sedation) compared with classical BZDs and barbiturates.  
   - *Bloom:* Evaluate  

---

## Big-Picture Framing

<div class="columns">
<div>

**Where do ‚ÄúZ-drugs‚Äù fit?**

- Act at **BZD site** on $GABA_A$ but  
  - **Structurally distinct** from benzodiazepines  
  - Often show **Œ±1-preferring** binding ‚Üí *more hypnotic*, less anxiolytic

**Key MedChem Theme**

- Keep **BZD-site binding pharmacophore**  
- Replace diazepine core with:
  - Imidazopyridine (**zolpidem**)  
  - Pyrazolopyrimidine (**zaleplon**)  
  - Cyclopyrrolone (**eszopiclone**)

</div>
<div>

![Non-BZD families](figures/Zdrug_classes_overview.jpg)

</div>
</div>

---

## üß© Non-BZD BZD-Site Pharmacophore (Conceptual)

**Shared binding ‚Äúlogic‚Äù vs BZDs**

- Aromatic / heteroaromatic **‚ÄúA ring‚Äù** for œÄ‚ÄìœÄ interaction  
- **H-bond acceptor** region (often an amide/urea carbonyl)  
- **Lipophilic tail** to occupy hydrophobic pocket  
- Geometry tuned to favor **Œ±1-containing** $GABA_A$ receptors

> Design goal: maintain **allosteric modulation** (‚Üë frequency of $Cl^-$ channel opening in presence of GABA) while sculpting **PK & side-effect profile**.

![Z-drug pharmacophore](figures/Zdrug_pharmacophore_map.jpg)

---

## Zolpidem ‚Äî Imidazopyridine Class

<div class="columns">
<div>

**Key structural features**

- **Imidazopyridine core** (no diazepine ring)  
- **p-Chlorophenyl** moiety ‚Üí lipophilic, interacts like BZD C-ring  
- **Amide side chain** (N,N-dimethylacetamide)  
- Moderately lipophilic ‚Üí good CNS penetration  

**SAR Highlights**

- Aromatic **p-Cl** helps mimic C7-Cl / C-ring substitution of BZDs  
- Amide carbonyl = H-bond acceptor, anchors to BZD site  
- Dimethyl substitution affects:
  - **Metabolic rate** (N-dealkylation, oxidation)  
  - Effective **half-life** (~2‚Äì3 h)

</div>
<div>

![Zolpidem structure](figures/zolpidem_structure.jpg)

</div>
</div>

---

## Zolpidem ‚Äî MedChem ‚Üí PK/PD

- **Onset:** Rapid (short tmax) due to lipophilicity and small size  
- **Metabolism:**  
  - Oxidation and hydroxylation (primarily CYP3A4; minor CYP2C9/1A2)  
  - Metabolites largely **inactive** ‚Üí short functional duration  
- **Clinical consequences:**  
  - Good for **sleep-onset insomnia**  
  - **Less daytime sedation** vs long-acting BZDs  
  - Still risk of:
    - Complex sleep behaviors  
    - Anterograde amnesia at higher doses

> PY1 check: connect **‚Äúsimple, lipophilic, oxidatively cleared‚Äù** ‚Üí short duration, low accumulation.

---

## Zaleplon ‚Äî Pyrazolopyrimidine Class

<div class="columns">
<div>

**Structural Motifs**

- **Pyrazolopyrimidine core**  
- **Nitrile group** and heteroatoms ‚Üí modulate electronics  
- Short, relatively **‚Äúfragile‚Äù side chain** ‚Üí rapid metabolism  

**Metabolism Driven Design**

- Major pathway: **aldehyde oxidase & CYP3A4**  
- Very short **elimination half-life** (~1 h)  
- Essentially **no active metabolites**

**Clinical Impact**

- **Ultra-short duration**  
- Good for **sleep-onset** and **middle-of-the-night awakenings**  
- Minimal next-day impairment ‚Üí but **rebound insomnia** possible

</div>
<div>

![Zaleplon structure](figures/zaleplon_structure.jpg)

</div>
</div>

---

## Eszopiclone ‚Äî Cyclopyrrolone Class

<div class="columns">
<div>

**Key Features**

- **Cyclopyrrolone** scaffold  
- Chiral: **eszopiclone = S-enantiomer** (active)  
- Multiple heteroatoms and a **lactam** functional group  
- More **polar** than zolpidem ‚Üí slightly longer **t¬Ω (~5‚Äì7 h)**

**MedChem ‚Üí PK**

- Oxidative metabolism (CYP3A4, CYP2E1)  
- Metabolites less active ‚Üí limited accumulation  
- Duration covers **sleep-onset + some maintenance**  

**Adverse Effects**

- Dysgeusia (‚Äúmetallic taste‚Äù) linked to heteroatom-rich scaffold  
- Residual morning sedation at higher doses

</div>
<div>

![Eszopiclone structure](figures/eszopiclone_structure.jpg)

</div>
</div>

---

## Comparing Z-Drugs vs Classical BZDs

| Feature                  | Classical BZDs                           | Z-Drugs                                 |
| :----------------------- | :--------------------------------------- | :-------------------------------------- |
| Core scaffold           | 1,4-benzodiazepine-2-one                | Heteroaromatic (imidazopyridine, etc.) |
| Binding site            | BZD site (Œ±‚ÄìŒ≥)                           | Same site, more **Œ±1-biased**          |
| t¬Ω range                | Short ‚Üí very long (active metabolites)  | Generally **short** (few hours)        |
| Active metabolites?     | Common (e.g., flurazepam, diazepam)     | Usually minimal / inactive             |
| Designed goal           | Broad: anxiety, seizures, insomnia      | Narrow: **insomnia/hypnosis**          |
| Amnesia risk            | Prominent (esp. triazolam)              | Present but somewhat reduced           |

> ML/NLP ‚Äúpattern‚Äù for students:  
> **More lipophilic + N-alkyl chains + aromatic BZD core ‚Üí longer t¬Ω via oxidation & active metabolites. Shorter, ‚Äúfragile‚Äù heteroaromatic scaffolds ‚Üí shorter t¬Ω, fewer active metabolites.**

---

## Other Non-BZD Hypnotics (Brief MedChem Touch)

### Doxepin (Low-dose for insomnia):contentReference[oaicite:2]{index=2}  

- Tricyclic antidepressant scaffold  
- At low doses, **H1 receptor antagonism** dominates  
- Multiple aromatic rings + side chains ‚Üí high lipophilicity; longish t¬Ω  
- MedChem risk: **polypharmacology** (NE transporter, muscarinic, Œ±1, 5-HT2A) ‚Üí side effects and drug‚Äìdrug interactions

---

## **Active Learning Slide** ‚Äî SAR Prediction

**Prompt (small-group or iRAT/TRAT):**

1. Replace zolpidem‚Äôs p-Cl with H. Predict:  
   - **‚Üì lipophilicity ‚Üí slower CNS entry + ‚Üì binding affinity**  

2. Add bulky group to zolpidem‚Äôs amide nitrogen (e.g., tertiary amide with large aryl). Predict:  
   - Steric interference with binding pocket ‚Üí **‚Üì potency**  

3. Modify zaleplon scaffold to block aldehyde oxidase metabolism. Predict:  
   - **‚Üë half-life, ‚Üë residual sedation**, ‚Üë accumulation risk

> Bloom: Analyze/Evaluate.  
> Use as **TRAT** discussion to connect structure ‚Üí clinical pearls.

---

## PY1 Assessment Blueprint (Non-BZD Hypnotics)

**Exam item types you can export later (ExamSoft/Canvas-ready):**

1. **Zolpidem SAR MCQ**  
   - Stem: Which modification would most likely **increase** zolpidem‚Äôs half-life?  
   - Options:
     - A. Removing p-Cl on the phenyl ring  
     - B. Adding a bulky lipophilic group to the amide side chain ‚úÖ  
     - C. Replacing the amide with a primary amine  
     - D. Introducing a polar carboxylic acid  
   - Bloom: *Apply/Analyze*  
   - Psychometric intent: Discriminate students who can link **lipophilicity + sterics ‚Üí PK**.

2. **Zaleplon PK rationale MCQ**  
   - Correct answer emphasizes **aldehyde oxidase-mediated rapid metabolism** leading to ultra-short t¬Ω.  
   - Include distractors that confuse Phase I vs Phase II or confuse with 3-OH BZDs.

3. **Case-based item**  
   - Elderly patient with early-morning driving; choose best Z-drug + dose timing based on PK.  
   - Bloom: *Analyze/Evaluate*.

> You can park these item stems in `assessments/L02_NonBZD_bank.md` in your repo for later JSON transformation.

---

## Wrap-Up / Take-Home Messages

- Different scaffolds, **same BZD-binding site** ‚Üí hypnotic selectivity via **Œ±1-favored binding**  
- Design levers:
  - Heteroaromatic cores  
  - ‚ÄúSoft‚Äù metabolic handles (aldehyde oxidase targets, oxidizable groups)  
  - Control over lipophilicity and polar surface  
- Z-drugs **mitigate**, but do not eliminate, risks: complex behaviors, dependence, amnesia.

**Next lecture:** Melatonin agonists, orexin antagonists, buspirone, and barbiturates (MedChem comparison.

---

